Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Serotonin reuptake

Beginning in the 1960s, ben2odia2epiae anxiolytics and hypnotics rapidly became the standard prescription dmg treatment. In the 1980s, buspkone [36505-84-7] (3), which acts as a partial agonist at the serotonin [50-67-9] (5-hydroxytryptamine, 5-HT) type lA receptor, was approved as treatment for generali2ed anxiety. More recently, selective serotonin reuptake inhibitors (SSRIs) have been approved for therapy of panic disorder and obsessive—compulsive behavior. [Pg.218]

SSRIs are well tolerated. Adverse effects for compounds in this class include nervousness, tremor, dizziness, headache, insomnia, sexual dysfunction, nausea, and diarrhea. In addition, the tricycHc antidepressant clomipramine (33), which is a potent nonselective serotonin reuptake inhibitor, is approved for treatment of obsessive—compulsive disorder. [Pg.227]

Treatment of Major Depression. Dmgs commonly used for the treatment of depressive disorders can be classified heuristicaHy iato two main categories first-generation antidepressants with the tricycHc antidepressants (TCAs) and the irreversible, nonselective monoamine—oxidase (MAO) inhibitors, and second-generation antidepressants with the atypical antidepressants, the reversible inhibitors of monoamine—oxidase A (RIMAs), and the selective serotonin reuptake inhibitors (SSRIs). Table 4 fists the available antidepressants. [Pg.229]

Venlafaxine (48) is a stmcturaHy novel phenylethylamine derivative that strongly inhibits both noradrenaline and serotonin reuptake. It lacks anticholinergic, antihistaminergic, and antiadrenergic side effects. As compared to placebo, most common adverse events are nausea, somnolence, dizziness, dry mouth, and sweating. Venlafaxine-treated patients also experienced more headaches and nausea, but less dry mouth, dizziness, and tremor than patients treated with comparator antidepressants. [Pg.232]

Future Outlook for Antidepressants. Third-generation antidepressants are expected to combine superior efficacy and improved safety, but are unlikely to reduce the onset of therapeutic action in depressed patients (179). Many dmgs in clinical development as antidepressive agents focus on estabhshed properties such as inhibition of serotonin, dopamine, and/or noradrenaline reuptake, agonistic or antagonistic action at various serotonin receptor subtypes, presynaptic tt2-adrenoceptor antagonism, or specific monoamine—oxidase type A inhibition. Examples include buspirone (3) (only... [Pg.233]

Selected for clinical trials as a compound to calm agitated patients, imipramine was relatively ineffective. However, it was observed to be effective in the treatment of certain depressed patients (38). Early studies on the mechanism of action showed that imipramine potentiates the effects of the catecholamines, primarily norepinephrine. This finding, along with other evidence, led to the hypothesis that the compound exerts its antidepressant effects by elevating norepinephrine levels at central adrenergic synapses. Subsequent studies have shown that the compound is a potent inhibitor of norepinephrine reuptake and, to a lesser extent, the uptake of serotonin, thus fitting the hypothesis that had been developed to explain the antidepressant actions ofMAOIs. [Pg.467]

Desipramine [50-47-5] (35) and nortriptyline [72-69-5] (36) are demethylated derivatives and principal metaboHtes of (32) and (33), respectively. Both compounds possess less sedative and stronger psychomotor effects than the tertiary amine counterparts, probably because tricycHcs containing secondary amine groups generally show greater selectivity for inhibiting the reuptake of norepinephrine compared with the reuptake of serotonin. Protriptyline [438-60-8] (37), a stmctural isomer of nortriptyline, is another important secondary amine that displays a similar clinical profile. [Pg.467]

Selective Serotonin Reuptake Inhibitors. In 1987, the FDA approved fluoxetine [54910-89-3] (42) for use in the treatment of major... [Pg.468]

Sibutramine (Table 1) has been in the market for several years and inhibits the reuptake of serotonin, noradrenaline and, to a lesser extent, dopamine. It acts... [Pg.159]

While these functions can be a carried out by a single transporter isoform (e.g., the serotonin transporter, SERT) they may be split into separate processes carried out by distinct transporter subtypes, or in the case of acetylcholine, by a degrading enzyme. Termination of cholinergic neurotransmission is due to acetylcholinesterase which hydrolyses the ester bond to release choline and acetic acid. Reuptake of choline into the nerve cell is afforded by a high affinity transporter (CHT of the SLC5 gene family). [Pg.836]

MDMA overdose as well as the concomitant consumption of selective serotonin reuptake inhibitors (SSRI) with other dmgs that exert serotoninergic effects (such as inhibitors of monoamine oxidase) can rapidly lead to the serotonin syndrome. Its symptoms, which are reversible upon cessation, of the drug include confusion, muscle rigidity in the lower limbs, and hyperthermia suggesting an acute reaction to serotonin overflow in the CNS. Blocking the function of SERT outside the brain causes side effects (e.g., nausea), which may be due to elevated 5HT however , impairment of transporter function is not equivalent to direct activation of 5HT recqrtors in causing adverse effects such as fibrosis and pulmonary hypertension. [Pg.841]

Noradrenaline transporters (NAT) are localized in the presynaptic plasma membrane of adrenergic nerve terminals. They belong to a family of proteins with 12 putative transmembrane proteins which are responsible for recycling of released neurotransmitters (noradrena-line/adrenaline, dopamine, serotonin, amino acid transmitters) back into the presynaptic nerve ending. Noradrenaline transporters can be blocked by a number of different antidepressant drags, including tricyclic antidepressants (e.g. desipramine) and selective noradrenaline reuptake inhibitors (e.g. reboxetine). [Pg.883]

The pharmacology of amphetamine is considerably more complex. It does not only block monoamine reuptake, but also directly inhibits the vesicular monoamine transporter, causing an increase in cytosolic but not vesicular dopamine concentration. This may lead to reverse transport of the amines via the membrane-bound transporters. Further mechanisms of amphetamine action are direct MAO inhibition and indirect release of both dopamine and serotonin in the striatum. [Pg.1039]

Selective serotonine reuptake inhibitor (SSRI) is an abbreviation for the class of antidepressants known as the Selective Serotonin Reuptake Inhibitors. Examples of SSRIs include fluoxetine, paroxetine, citalopram, and sertraline. These drugs selectively inhibit the serotonin transporter thus prolonging the synaptic lifespan of the neurotransmitter serotonin. [Pg.1113]

Indeed, 5-HT is also a substrate for the 5-HT transporter, itself an important player in the treatment of depression, and more recently for the whole range of anxiety disorders spectrum (GAD, OCD, social and other phobias, panic and post-traumatic stress disorders). It is the target for SSRIs (selective serotonin reuptake inhibitors) such as fluoxetine, paroxetine, fluvoxamine, and citalopram or the more recent dual reuptake inhibitors (for 5-HT and noradrenaline, also known as SNRIs) such as venlafaxine. Currently, there are efforts to develop triple uptake inhibitors (5-HT, NE, and DA). Further combinations are possible, e.g. SB-649915, a combined 5-HTia, 5-HT1b, 5-HT1d inhibitor/selective serotonin reuptake inhibitor (SSRI), is investigated for the treatment of major depressive disorder. [Pg.1124]

Tranquilizers (also called antianxiety drugs) are used to treat a variety of psychiatric disorders which go along with anxiety (anxiety disorders). Serotonin-reuptake inhibitors and the benzodiazepines are the most commonly employed drugs for the treatment of common clinical anxiety disorders. [Pg.1223]

VMATs are not inhibited by drugs such as cocaine, tricyclic antidqnessants and selective serotonin reuptake inhibitors that affect plasma membrane monoamine transport. Amphetamines have relatively selective effects on monoaminergic cells due to selective uptake by plasma membrane monoamine transporters, but their effect appears to be mediated by their ability as weak bases to reduce ApH, the driving force for vesicular monoamine transport that leads to efflux of the vesicular contents into the cytoplasm. [Pg.1282]

The TCAs, such as amitriptyline (Elavil) and dox-epin (Sinequan), inhibit reuptake of norepinephrine or serotonin at the presynaptic neuron. Drug classified as MAOIs inhibit the activity of monoamine oxidase a complex enzyme system that is responsible for breaking down amines. This results in an increase in endogenous epinephrine, norepinephrine and serotonin in the nervous system. An increase in these neurohormones results in stimulation of the CNS. The action of the SSRIs is linked to their inhibition of CNS neuronal uptake of serotonin (a CNS neurotransmitter). The increase in serotonin levels is thought to act as a stimulant to reverse depression. [Pg.282]

Antidepressants Trazodone, mirtazapine, paroxetine, other selective serotonin reuptake inhibitors venlafaxine... [Pg.135]

The various stimulants have no obvious chemical relationships and do not share primary neurochemical effects, despite their similar behavioral effects. Cocaines chemical strucmre does not resemble that of caffeine, nicotine, or amphetamine. Cocaine binds to the dopamine reuptake transporter in the central nervous system, effectively inhibiting dopamine reuptake. It has similar effects on the transporters that mediate norepinephrine and serotonin reuptake. As discussed later in this chapter in the section on neurochemical actions mediating stimulant reward, dopamine is very important in the reward system of the brain the increase of dopamine associated with use of cocaine probably accounts for the high dependence potential of the drug. [Pg.186]


See other pages where Serotonin reuptake is mentioned: [Pg.227]    [Pg.228]    [Pg.232]    [Pg.232]    [Pg.468]    [Pg.469]    [Pg.469]    [Pg.218]    [Pg.219]    [Pg.41]    [Pg.112]    [Pg.113]    [Pg.161]    [Pg.211]    [Pg.213]    [Pg.260]    [Pg.788]    [Pg.841]    [Pg.872]    [Pg.907]    [Pg.1113]    [Pg.1155]    [Pg.1502]    [Pg.281]    [Pg.281]    [Pg.284]    [Pg.15]    [Pg.30]    [Pg.92]    [Pg.119]    [Pg.199]   
See also in sourсe #XX -- [ Pg.98 ]

See also in sourсe #XX -- [ Pg.219 , Pg.224 ]




SEARCH



Antidepressants selective serotonin reuptake

Antidepressants selective serotonin reuptake inhibitors

Antidepressants serotonin reuptake inhibitors

Antidepressants serotonin-norepinephrine reuptake inhibitors

Antidepressants serotonin/noradrenaline reuptake inhibitor

Antipsychotic drugs selective serotonin reuptake inhibitors with

Antipsychotic drugs serotonin reuptake inhibitors

Anxiety selective serotonin reuptake inhibitors

Children selective serotonin reuptake

Depression selective serotonin reuptake inhibitors

Depression serotonin reuptake inhibitor

Depressive disorders selective serotonin reuptake inhibitors

Dual serotonin-dopamine reuptake inhibitors

Dual serotonin-norepinephrine reuptake

Dual serotonin-norepinephrine reuptake inhibitors

Inhibition serotonin reuptake

Insomnia selective serotonin reuptake inhibitors

Medication serotonin reuptake inhibitors specific

Medications selective serotonin reuptake inhibitors

Mirtazapine selective serotonin reuptake inhibitors with

Monoamine transporters serotonin reuptake inhibitor

Nefazodone selective serotonin reuptake inhibitors with

Nonselective serotonin reuptake

Nonselective serotonin reuptake inhibitors

Norepinephrine reuptake with serotonin inhibition

Obsessive-compulsive disorder selective serotonin reuptake inhibitors

Panic disorder selective serotonin reuptake inhibitors

Pharmacology serotonin reuptake

Posttraumatic stress disorder selective serotonin reuptake inhibitors

Reboxetine selective serotonin reuptake inhibitors with

Reuptake

Reuptake Dual Selective Serotonin Norepinephrine

SNRI (serotonin norepinephrine reuptake

SNRIs (serotonin-norepinephrine reuptake

SSNRI (selective serotonin norepinephrine Reuptake

SSRIs (selective serotonin reuptake

SSRIs (selective serotonin reuptake side effects

SSRIs (serotonin reuptake

SSRIs (serotonin reuptake side effects

SSRls (selective serotonin reuptake

Schizophrenia Selective serotonin reuptake inhibitors

Selected serotonin reuptake inhibitors

Selective Serotonin-Norepinephrine Reuptake Inhibitors

Selective Serotonine Reuptake Inhibitors

Selective serotonin and norepinephrine reuptake inhibitors

Selective serotonin reuptake

Selective serotonin reuptake 5-Hydroxytryptamine

Selective serotonin reuptake Prozac

Selective serotonin reuptake activation effects

Selective serotonin reuptake adverse effects

Selective serotonin reuptake fluoxetine

Selective serotonin reuptake fluoxetine, paroxetine, sertraline)

Selective serotonin reuptake indications

Selective serotonin reuptake inhibitor behavioral

Selective serotonin reuptake inhibitor metabolic

Selective serotonin reuptake inhibitors

Selective serotonin reuptake inhibitors (SSRIs side effects

Selective serotonin reuptake inhibitors . See

Selective serotonin reuptake inhibitors Citalopram Fluoxetine

Selective serotonin reuptake inhibitors Fluvoxamine Paroxetine Sertraline

Selective serotonin reuptake inhibitors MAOIs

Selective serotonin reuptake inhibitors MDMA)

Selective serotonin reuptake inhibitors SSRIs)

Selective serotonin reuptake inhibitors about

Selective serotonin reuptake inhibitors action

Selective serotonin reuptake inhibitors administration

Selective serotonin reuptake inhibitors adverse effects

Selective serotonin reuptake inhibitors alprazolam

Selective serotonin reuptake inhibitors amphetamines

Selective serotonin reuptake inhibitors analysis

Selective serotonin reuptake inhibitors and

Selective serotonin reuptake inhibitors anxiety disorders

Selective serotonin reuptake inhibitors anxiety from

Selective serotonin reuptake inhibitors anxiety with

Selective serotonin reuptake inhibitors anxiolytics

Selective serotonin reuptake inhibitors benzodiazepines

Selective serotonin reuptake inhibitors buspirone

Selective serotonin reuptake inhibitors characteristics

Selective serotonin reuptake inhibitors chemical structures

Selective serotonin reuptake inhibitors children

Selective serotonin reuptake inhibitors citalopram

Selective serotonin reuptake inhibitors classification

Selective serotonin reuptake inhibitors clinical trials

Selective serotonin reuptake inhibitors clozapine

Selective serotonin reuptake inhibitors death

Selective serotonin reuptake inhibitors depression from

Selective serotonin reuptake inhibitors discontinuation

Selective serotonin reuptake inhibitors discontinuation syndrome

Selective serotonin reuptake inhibitors dosing

Selective serotonin reuptake inhibitors drug administration

Selective serotonin reuptake inhibitors drug interactions

Selective serotonin reuptake inhibitors drug overdose

Selective serotonin reuptake inhibitors drug withdrawal

Selective serotonin reuptake inhibitors drugs

Selective serotonin reuptake inhibitors during pregnancy

Selective serotonin reuptake inhibitors effects

Selective serotonin reuptake inhibitors efficacy

Selective serotonin reuptake inhibitors enantiomers

Selective serotonin reuptake inhibitors enhanced

Selective serotonin reuptake inhibitors escitalopram

Selective serotonin reuptake inhibitors extended-release

Selective serotonin reuptake inhibitors fluoxetine

Selective serotonin reuptake inhibitors fluvoxamine

Selective serotonin reuptake inhibitors gastrointestinal

Selective serotonin reuptake inhibitors general

Selective serotonin reuptake inhibitors haloperidol

Selective serotonin reuptake inhibitors hyponatremia with

Selective serotonin reuptake inhibitors immediate

Selective serotonin reuptake inhibitors in children

Selective serotonin reuptake inhibitors in children and adolescents

Selective serotonin reuptake inhibitors in obsessive-compulsive disorder

Selective serotonin reuptake inhibitors indications

Selective serotonin reuptake inhibitors interactions

Selective serotonin reuptake inhibitors labeling

Selective serotonin reuptake inhibitors lactation

Selective serotonin reuptake inhibitors limits

Selective serotonin reuptake inhibitors lithium

Selective serotonin reuptake inhibitors liver

Selective serotonin reuptake inhibitors long-term effects

Selective serotonin reuptake inhibitors mediation

Selective serotonin reuptake inhibitors metabolism

Selective serotonin reuptake inhibitors moclobemide

Selective serotonin reuptake inhibitors monoamine oxidase

Selective serotonin reuptake inhibitors mood disorders from

Selective serotonin reuptake inhibitors nefazodone

Selective serotonin reuptake inhibitors nervous system

Selective serotonin reuptake inhibitors olanzapine

Selective serotonin reuptake inhibitors overdose

Selective serotonin reuptake inhibitors overview

Selective serotonin reuptake inhibitors paroxetine

Selective serotonin reuptake inhibitors pharmacodynamic

Selective serotonin reuptake inhibitors pharmacokinetic

Selective serotonin reuptake inhibitors pharmacology

Selective serotonin reuptake inhibitors pindolol

Selective serotonin reuptake inhibitors risperidone

Selective serotonin reuptake inhibitors second-generation effects

Selective serotonin reuptake inhibitors selectivity differences

Selective serotonin reuptake inhibitors sertraline

Selective serotonin reuptake inhibitors structure

Selective serotonin reuptake inhibitors suicidality from

Selective serotonin reuptake inhibitors toxicity

Selective serotonin reuptake inhibitors tramadol

Selective serotonin reuptake inhibitors trazodone

Selective serotonin reuptake inhibitors tricyclic antidepressant interactions with

Selective serotonin reuptake inhibitors tricyclic antidepressants

Selective serotonin reuptake inhibitors triptans

Selective serotonin reuptake inhibitors venlafaxine

Selective serotonin reuptake inhibitors with stimulants

Selective serotonin reuptake inhibitors withdrawal

Selective serotonin reuptake inhibitors withdrawal from

Selective serotonin reuptake inhibitors, 128 sumatriptan

Selective serotonin reuptake interactions

Selective serotonin reuptake management

Selective serotonin reuptake pharmacological properties

Selective serotonin reuptake receptor

Selective serotonin reuptake risks

Selective serotonin reuptake side effects

Selective serotonin reuptake with antipsychotics

Selective serotonin reuptake with monoamine oxidase

Selective serotonin reuptake with tricyclic antidepressants

Selective serotonin reuptake withdrawal

Serotonin and noradrenalin reuptake

Serotonin and noradrenalin reuptake inhibitors

Serotonin and noradrenaline reuptake

Serotonin and noradrenaline reuptake inhibition

Serotonin and noradrenaline reuptake inhibitors

Serotonin and norepinephrine reuptake inhibitors

Serotonin and norepinephrine reuptake inhibitors SNRIs)

Serotonin antagonist reuptake inhibitor

Serotonin antagonists and reuptake inhibitors

Serotonin neuronal reuptake

Serotonin noradrenaline reuptake

Serotonin noradrenergic reuptake inhibitors

Serotonin norepinephrine reuptake inhibitors

Serotonin reuptake blocked

Serotonin reuptake channel

Serotonin reuptake enhancers

Serotonin reuptake inhibitors

Serotonin reuptake inhibitors agitation caused

Serotonin reuptake inhibitors effects

Serotonin reuptake inhibitors patients with depression

Serotonin reuptake inhibitors receptor specificity

Serotonin reuptake inhibitors seizures caused

Serotonin reuptake inhibitors toxicity

Serotonin reuptake inhibitors, selective dosage

Serotonin reuptake inhibitors, selective interaction with other drugs

Serotonin reuptake inhibitors, selective pharmacokinetics

Serotonin reuptake inhibitors, selective side effects

Serotonin reuptake transporter

Serotonin reuptake transporters (SERT

Serotonin-norepinephrine reuptake

Serotonin-norepinephrine reuptake dosage

Serotonin-norepinephrine reuptake inhibitor SNRI)

Serotonin-norepinephrine reuptake inhibitor drug

Serotonin-norepinephrine reuptake inhibitors SNRIs)

Serotonin-norepinephrine reuptake pharmacokinetics

Serotonin-norepinephrine reuptake relative potency

Serotonin-norepinephrine reuptake side effects

Serotonin-selective reuptake additional indications

Serotonin-specific reuptake inhibitor

Serotonin/noradrenaline reuptake inhibitors

Serotonin/noradrenaline reuptake inhibitors SNRIs)

Social anxiety disorder selective serotonin reuptake inhibitors

Specific serotonin reuptake

Specific serotonin reuptake inhibitors (SSRIs

Subject selective serotonin reuptake inhibitors

Suicide selective serotonin reuptake

Trazodone selective serotonin reuptake inhibitors with

Tricyclic antidepressants selective serotonin reuptake inhibitor interactions

© 2024 chempedia.info